iOnctura: Funding, Investors & Team (Sep 2026)
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
iOnctura has raised $21.9M across 5 funding rounds on record, the most recent an undisclosed round of $400k announced in May 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
iOnctura Company Profile and Key Stats
Latest funding round on record: May 2024.
iOnctura Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
iOnctura raised $5.1M in an undisclosed round announced in Jul 2020.
2.2 years later, a Debt Financing of $410k was announced in Sep 2022.
3 months later, an undisclosed round of $16.0M was announced in Dec 2022.
5 months later, an undisclosed round was announced in May 2023 with no disclosed amount.
1 years later, an undisclosed round of $400k was announced in May 2024.
iOnctura Founders and Leadership Team
Contact details for the iOnctura team: 1 of 1 has an email address on file.
Start 14-day free trial →iOnctura Funding Compared to Other Biotechnology Startups
iOnctura's latest round of $400k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like iOnctura in Biotechnology and Genève
Companies Similar to iOnctura
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
iOnctura Funding FAQs
What does iOnctura do?
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
How much funding has iOnctura raised?
iOnctura has raised $21.9M across 5 rounds on record. The most recent is an undisclosed round of $400k announced in May 2024.
When did iOnctura last raise funding?
iOnctura's most recent funding round on record is an undisclosed round of $400k, announced in May 2024.
Who is the CEO of iOnctura?
Catherine Pickering is listed as CEO at iOnctura.
Where is iOnctura headquartered?
iOnctura is based in Genève, Geneve, Switzerland.
How many employees does iOnctura have?
iOnctura is in the 11-50 employee band.
How does iOnctura's funding compare to other Biotechnology startups?
iOnctura's latest round of $400k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's iOnctura Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for iOnctura is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.